• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scholar Rock Holding Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    6/28/24 8:49:01 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    0001727196false--12-3100017271962024-06-272024-06-27

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event Reported): June 27, 2024

    ​

    Scholar Rock Holding Corporation

    (Exact Name of Registrant as Specified in Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

        

    001-38501

        

    82-3750435

    (State or Other Jurisdiction of
    Incorporation)

    ​

    (Commission File Number)

    ​

    (I.R.S. Employer Identification Number)

    ​

    301 Binney Street, 3rd Floor, Cambridge, MA 02142

    (Address of Principal Executive Offices) (Zip Code)

    ​

    (857) 259-3860

    (Registrant’s telephone number, including area code)

    ​

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

    ​

    SRRK

    ​

    Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 3.03. Material Modification to Rights of Security Holders.

    ​

    As further described under Item 5.07 of this Current Report on Form 8-K, on June 27, 2024 at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Scholar Rock Holding Corporation (the “Company”), and upon the recommendation of the Board of Directors (the “Board”) of the Company, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law (the “Officer Exculpation Amendment”). The Officer Exculpation Amendment was previously approved by the Board, subject to stockholder approval.

    ​

    The Officer Exculpation Amendment is described in detail under “Proposal 4 - Amend The Company’s Amended And Restated Certificate Of Incorporation To Limit The Liability Of Certain Officers Of The Company” beginning on page 19 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024 (the “Proxy Statement”) in connection with the Annual Meeting. The text of the Officer Exculpation Amendment was included in Annex B of the Proxy Statement.

    ​

    The Officer Exculpation Amendment became effective upon its filing with the Secretary of State of the State of Delaware on June 27, 2024.

    ​

    The foregoing description of the Officer Exculpation Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the certificate of amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and incorporated herein by reference.

    ​

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    ​

    To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

    ​

    As further described under Item 5.07 of this Current Report on this Form 8-K, at the Annual Meeting, and upon the recommendation of the Board, the Company’s stockholders approved a Certificate of Amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.001 per share (“Common Stock”, such amendment, the “Authorized Shares Amendment”). The Authorized Shares Amendment was previously approved by the Board, subject to stockholder approval.

    ​

    The Authorized Shares Amendment is described in detail under “Proposal 3 - Amend The Company’s Amended And Restated Certificate Of Incorporation To Increase The Number Of Authorized Shares Of Common Stock From 150,000,000 To 300,000,000” beginning on page 16 of the Proxy Statement in connection with the Annual Meeting. The text of the Authorized Shares Amendment was included in Annex A of the Proxy Statement.

    ​

    The Authorized Shares Amendment became effective upon its filing with the Secretary of State of the State of Delaware on June 27, 2024.

    ​

    The foregoing description of the Authorized Shares Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the certificate of amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and incorporated herein by reference.

    ​

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    During the Annual Meeting, the Company’s stockholders considered and voted on the six proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement. The final voting results are set forth below.

    ​

    Proposal 1 - Election of Directors

     

    The stockholders elected each of the persons named below to serve as a Class III director of the Company for a three-year term that expires at the Company’s annual meeting of stockholders in 2027 and until their successors, if any,

    are duly elected and qualified, subject to their earlier death, resignation or removal. The results of such vote were as follows:

     

    Director Name

     

    Votes For

     

    Votes Withheld

    Broker Non-Votes

     

    Richard Brudnick

     

    62,726,053

     

    8,216,814

    5,223,279

     

    Jeffrey S. Flier, M.D.

     

    56,709,862

     

    14,233,005

    5,223,279

     

    Akshay Vaishnaw, M.D.,Ph.D.

     

    64,032,596

     

    6,910,271

    5,223,279

     

     

    Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

     

    The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of such vote were as follows:

     

    Votes For

     

     

    Votes Against

     

     

    Abstentions

     

    76,077,049

    ​

    ​

    ​

    ​

    81,644

    ​

    ​

    7,453

    ​

     

    ​

    Proposal 3 – Amendment of the Company’s Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock

    The stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The results of such vote were as follows:

    Votes For

     

     

    Votes Against

     

     

    Abstentions

    ​

     73,832,131

    ​

    ​

    2,323,602

    ​

    ​

    10,413

    ​

    ​

    Proposal 4 – Amendment of the Company’s Amended and Restated Certificate of Incorporation to Limit the Liability of Certain Officers of the Company

    The stockholders approved an amendment to the Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. The results of such vote were as follows:

    Votes For

     

     

    Votes Against

     

     

    Abstentions

    Broker Non-Votes

     61,173,475

    ​

    ​

    9,760,918

    ​

    ​

    8,474

    5,223,279

    ​

    Proposal 5 – Approval of the Compensation of the Company’s Named Executive Officers on a Non-Binding, Advisory Basis

    The stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of such vote were as follows:

    ​

    Votes For

     

     

    Votes Against

     

     

    ​

    Abstentions

    Broker Non-Votes

    69,061,313

    ​

    ​

    1,773,153

    ​

    ​

    ​

    108,401

    5,223,279

    ​

    Proposal 6 – Approval of the Preferred Frequency for the Advisory Vote on the Compensation of the Company’s Named Executed Officers

    ​

    The stockholders approved, on a non-binding, advisory basis, the preferred frequency of the advisory votes on compensation of the Company’s named executive officers. The results of such vote were as follows:

    ​

    ​

    1 Year

     

     

    2 Years

     

     

    ​

    3 Years

    Abstentions

    Broker Non-Votes

     70,755,855

    ​

    ​

    14,133

    ​

    ​

    ​

    55,268

    117,611

    5,223,279

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.

     

    Description

    ​

    ​

    ​

    3.1

    ​

    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Scholar Rock Holding Corporation.

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    SIGNATURE

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Scholar Rock Holding Corporation

     

     

     

    Date: June 28, 2024

    By:

    /s/ Junlin Ho

     

     

    Junlin Ho

     

     

    General Counsel and Corporate Secretary

    ​

    ​

    ​

    Get the next $SRRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    1/9/2026$55.00Buy
    Citigroup
    11/18/2025$42.00Outperform
    Wolfe Research
    10/9/2025$53.00Buy
    BofA Securities
    9/17/2025$45.00Overweight
    Barclays
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany Secured new debt facility, providing up to $

    3/3/26 7:00:00 AM ET
    $OWL
    $SRRK
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:

    2/18/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    SEC Filings

    View All

    Amendment: Scholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K/A - Scholar Rock Holding Corp (0001727196) (Filer)

    3/3/26 4:30:41 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Scholar Rock Holding Corporation

    S-8 - Scholar Rock Holding Corp (0001727196) (Filer)

    3/3/26 7:20:55 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Scholar Rock Holding Corporation

    10-K - Scholar Rock Holding Corp (0001727196) (Filer)

    3/3/26 7:16:38 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Scholar Rock with a new price target

    Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00

    11/18/25 8:27:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Scholar Rock with a new price target

    BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00

    10/9/25 8:29:07 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $399,351 worth of shares (8,484 units at $47.07), decreasing direct ownership by 8% to 98,445 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/25/26 5:55:24 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENERAL COUNSEL Ho Junlin sold $445,740 worth of shares (9,580 units at $46.53), decreasing direct ownership by 4% to 241,545 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/19/26 4:30:12 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF MEDICAL OFFICER Marantz Jing L. sold $193,418 worth of shares (4,157 units at $46.53), decreasing direct ownership by 3% to 126,012 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/19/26 4:30:14 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany Secured new debt facility, providing up to $

    3/3/26 7:00:00 AM ET
    $OWL
    $SRRK
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:

    2/18/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care